These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38990319)

  • 21. Do Integrase Inhibitors Cause Weight Gain?
    Wood BR
    Clin Infect Dis; 2020 Mar; 70(7):1275-1277. PubMed ID: 31100105
    [No Abstract]   [Full Text] [Related]  

  • 22. Assessing the risk of dolutegravir for women of childbearing potential.
    Schomaker M; Davies MA; Cornell M; Ford N
    Lancet Glob Health; 2018 Sep; 6(9):e958-e959. PubMed ID: 30049617
    [No Abstract]   [Full Text] [Related]  

  • 23. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
    Phillips AN; Venter F; Havlir D; Pozniak A; Kuritzkes D; Wensing A; Lundgren JD; De Luca A; Pillay D; Mellors J; Cambiano V; Bansi-Matharu L; Nakagawa F; Kalua T; Jahn A; Apollo T; Mugurungi O; Clayden P; Gupta RK; Barnabas R; Revill P; Cohn J; Bertagnolio S; Calmy A
    Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid.
    Cabrera RM; Souder JP; Steele JW; Yeo L; Tukeman G; Gorelick DA; Finnell RH
    AIDS; 2019 Nov; 33(13):1967-1976. PubMed ID: 31259764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
    Banda FM; Powis KM; Sun S; Makhema J; Masasa G; Yee LM; Jao J
    AIDS; 2020 Dec; 34(15):2336-2337. PubMed ID: 32910067
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
    Nguyen B; Foisy MM; Hughes CA
    Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
    Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
    AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV Drug May Increase Risk of Neural Tube Birth Defects.
    Aschenbrenner DS
    Am J Nurs; 2019 Jan; 119(1):27. PubMed ID: 30589699
    [No Abstract]   [Full Text] [Related]  

  • 29. Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients.
    Mahlab-Guri K; Asher I; Rosenberg-Bezalel S; Elbirt D; Burke M; Sthoeger ZM
    Medicine (Baltimore); 2016 Nov; 95(47):e5465. PubMed ID: 27893693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dolutegravir becomes first choice for HIV.
    Rahimi S
    Lancet Infect Dis; 2019 Sep; 19(9):937-938. PubMed ID: 31478520
    [No Abstract]   [Full Text] [Related]  

  • 31. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
    Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
    N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two cases of neural tube defects with dolutegravir use at conception in south Brazil.
    Kreitchmann R; Oliveira FR; Sprinz E
    Braz J Infect Dis; 2021; 25(2):101572. PubMed ID: 33852885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
    Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What will it take to refute the possible safety signal for dolutegravir and neural tube defects?
    Zash RM
    BJOG; 2019 Oct; 126(11):1346. PubMed ID: 31283097
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
    Mofenson LM; Pozniak AL; Wambui J; Raizes E; Ciaranello A; Clayden P; Ehrenkranz P; Fakoya A; Hill A; Khoo S; Mahaka I; Modi S; Moore C; Phillips A; Siberry G; Sikwese K; Thorne C; Watts HD; Doherty M; Ford NP
    J Int AIDS Soc; 2019 Jul; 22(7):e25352. PubMed ID: 31298496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
    Chan P; Goh O; Kroon E; Colby D; Sacdalan C; Pinyakorn S; Prueksakaew P; Reiss P; Ananworanich J; Valcour V; Spudich S; Paul R;
    AIDS Res Ther; 2020 Jan; 17(1):1. PubMed ID: 31907064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letter to the Editor: Dolutegravir Monotherapy and Body Weight Gain in Antiretroviral Naïve Patients.
    Lanzafame M; Rizzardo S; Lattuada E; Luise D; Vento S
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):771-773. PubMed ID: 35815473
    [No Abstract]   [Full Text] [Related]  

  • 39. Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect.
    Yombi JC
    AIDS Rev; 2018; 20(1):14-26. PubMed ID: 29628511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dolutegravir and Folic Acid Interaction during Neural System Development in Zebrafish Embryos.
    Zizioli D; Quiros-Roldan E; Ferretti S; Mignani L; Tiecco G; Monti E; Castelli F; Zanella I
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.